===============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 6, 2007
Critical Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50767 04-3523569
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
60 Westview Street, Lexington, Massachusetts 02421
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (781) 402-5700
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
===============================================================================
Item 2.02. Results of Operations and Financial Condition.
On February 8, 2007, Critical Therapeutics, Inc. (the "Company") announced its
financial results for the quarter and year ended December 31, 2006. The Company
also provided guidance regarding anticipated quarterly ZYFLO sales during 2007,
total and per share net loss for 2007 and the first quarter of 2007, research
and development expenses for 2007 and net cash expenditures for the first
quarter of 2007. The full text of the press release issued in connection with
the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K and Exhibit 99.1 attached hereto shall be
deemed incorporated by reference in any registration statement previously or
subsequently filed by the Company under the Securities Act of 1933, as amended,
except to the extent that such information is superseded by information as of a
subsequent date that is included or incorporated by reference into such
registration statement.
Item 5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On February 6, 2007, Nicholas Galakatos, Ph.D., a class III director, notified
the Company that he does not plan to seek reelection for another term to the
Company's board of directors. Dr. Galakatos's term as a director is scheduled to
expire at the Company's 2007 annual meeting of stockholders.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: February 8, 2007 CRITICAL THERAPEUTICS, INC.
By: /s/ Frank E. Thomas
Frank E. Thomas
-------------------------------------
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press release dated February 8, 2007.